AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34672949 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus remdesivir
Number of subjects: 969
Study 32618258 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive zinc (PZ) tablets (7 mg/day)
Number of subjects: 720
Study 32618258 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient powder (MNP; containing 10 mg zinc and 14 other micronutrients)
Number of subjects: 720
Study 32618258 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic zinc (TZ) supplements for diarrhea treatment (20 mg/day for 10 days)
Number of subjects: 720
Study 32618258 — intervention group
Group type: COMPARATOR
Intervention: Placebo powder
Number of subjects: 720
Study 35449200 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-vision contact lenses (Lens 1)
Number of subjects: 19
Study 35449200 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive contact lenses (Lens 2)
Number of subjects: 19
Study 35449200 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifocal contact lenses (Lens 3)
Number of subjects: 19
Study 34290965 — intervention group
Group type: EXPERIMENTAL
Intervention: Saffron (100 mg/day)
Number of subjects: 55
Study 34290965 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 32963047 — intervention group
Group type: EXPERIMENTAL
Intervention: Romilkimab 200 mg subcutaneously once a week for 24 weeks
Number of subjects: 97
Study 32963047 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study 35242094 — intervention group
Group type: EXPERIMENTAL
Intervention: Liuzijue Qigong (LQG) exercise combined with conventional rehabilitation training
Number of subjects: 160
Study 35242094 — intervention group
Group type: COMPARATOR
Intervention: Core Stability Training (CST) combined with conventional rehabilitation training
Number of subjects: 160
Study 34550903 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment group
Number of subjects: 302
Study 34550903 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 302
Study 34530470 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban 2.5 mg twice daily
Number of subjects: 600
Study 34530470 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 600
Study 34529114 — intervention group
Group type: COMPARATOR
Intervention: Caffeine 0 mg/kg
Number of subjects: 100
Study 34529114 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 2 mg/kg
Number of subjects: 100
Study 34529114 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 4 mg/kg
Number of subjects: 100
Study 34529114 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine with CYP1A2 (rs762551) genotype
Number of subjects: 100
Study 34625016 — intervention group
Group type: EXPERIMENTAL
Intervention: Working Together intervention (n=20)
Number of subjects: 40
Study 34625016 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group (n=20)
Number of subjects: 40
Study 32569031 — intervention group
Group type: EXPERIMENTAL
Intervention: Lubiprostone
Number of subjects: 3209
Study 32569031 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3209
Study 33160407 — intervention group
Group type: EXPERIMENTAL
Intervention: Pheromone + insecticide (PI)
Number of subjects: 3145
Study 33160407 — intervention group
Group type: EXPERIMENTAL
Intervention: Dog collars (DC)
Number of subjects: 3145
Study 33160407 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 3145
Study 35927505 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP and lifestyle intervention
Number of subjects: 60
Study 35927505 — intervention group
Group type: COMPARATOR
Intervention: CPAP only (control)
Number of subjects: 60
Study 32672145 — intervention group
Group type: EXPERIMENTAL
Intervention: Attachment and Biobehavioral Catch-up (ABC) intervention
Number of subjects: 131
Study 32672145 — intervention group
Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 131
Study 32691672 — intervention group
Group type: EXPERIMENTAL
Intervention: BIOF2 (bioactive cell-free formulation)
Number of subjects: 3
Study 32468686 — intervention group
Group type: EXPERIMENTAL
Intervention: Video psychoeducation
Number of subjects: 0
Study 32468686 — intervention group
Group type: COMPARATOR
Intervention: Brochure psychoeducation
Number of subjects: 0
Study 33474962 — intervention group
Group type: COMPARATOR
Intervention: Full endoscopic discectomy
Number of subjects: 75
Study 33474962 — intervention group
Group type: COMPARATOR
Intervention: Full endoscopic discectomy and annular repair
Number of subjects: 75
Study 33474962 — intervention group
Group type: EXPERIMENTAL
Intervention: Full endoscopic discectomy annular repair and ACP intradiscal injection
Number of subjects: 75
Study 36456831 — intervention group
Group type: EXPERIMENTAL
Intervention: Strategy 1 and Strategy 2 (combined)
Number of subjects: 247
Study 36456831 — intervention group
Group type: EXPERIMENTAL
Intervention: Strategy 2
Number of subjects: 247
Study 36456831 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 247
Study 34384742 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary computed tomography (CTA)
Number of subjects: 10001
Study 34384742 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-coronary vascular disease (NCVD)
Number of subjects: 10001
Study 34384742 — intervention group
Group type: EXPERIMENTAL
Intervention: NCVD
Number of subjects: 10001
Study 36368290 — intervention group
Group type: EXPERIMENTAL
Intervention: ELLIPTA inhaler
Number of subjects: 114
Study 36368290 — intervention group
Group type: COMPARATOR
Intervention: BREEZHALER inhaler
Number of subjects: 114
Study 33965187 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Number of subjects: 60
Study 33965187 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 33965187 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival, progression-free survival, relapse rate, and nonrelapse mortality
Number of subjects: 60
Study 32135337 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep restriction (SR) - reduced by 1.5 hours a night for 6 weeks
Number of subjects: 41
Study 32135337 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep restriction (SR)
Number of subjects: 41
Study 32135337 — intervention group
Group type: COMPARATOR
Intervention: Habitual sleep (HS)
Number of subjects: 41
Study 35147905 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-session skin cancer prevention curriculum based on Protection Motivation Theory (PMT)
Number of subjects: 104
Study 35147905 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 104
Study 32061834 — intervention group
Group type: EXPERIMENTAL
Intervention: Couple-Based Meditation (CBM) program; 4 weekly sessions of 60 minutes each via FaceTime.
Number of subjects: 22
Study 32061834 — intervention group
Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 22
Study 35063205 — intervention group
Group type: EXPERIMENTAL
Intervention: LCω3 (MAG‐EPA 3 g daily)
Number of subjects: 130
Study 35063205 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study 35063205 — intervention group
Group type: EXPERIMENTAL
Intervention: Open retropubic radical prostatectomy
Number of subjects: 130
Study 33094551 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 - SmearOFF™
Number of subjects: 52
Study 33094551 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 3 - Qmix®
Number of subjects: 52
Study 33094551 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 - 17% EDTA, Saline and 2% Chlorhexidine solution
Number of subjects: 52
Study 33094551 — intervention group
Group type: COMPARATOR
Intervention: Group 4 - saline control
Number of subjects: 52
Study 32564499 — intervention group
Group type: EXPERIMENTAL
Intervention: Binaural Beats (BB) at 5Hz for 30 minutes
Number of subjects: 0
Study 32564499 — intervention group
Group type: EXPERIMENTAL
Intervention: Binaural Beats (BB)
Number of subjects: 0
Study 32564499 — intervention group
Group type: COMPARATOR
Intervention: Sham Stimulation (SS)
Number of subjects: 0
Study 35459252 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive telephone-based peer support for breastfeeding
Number of subjects: 10
Study 36316913 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefopam (20 mg)
Number of subjects: 50
Study 36316913 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (NSS)
Number of subjects: 50
Study 34499174 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent treatment (pain neuroscience education, therapeutic exercise, cognitive behavioral therapy, and mindfulness, delivered in 2-hour weekly sessions for 12 weeks)
Number of subjects: 272
Study 34499174 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent treatment
Number of subjects: 272
Study 34499174 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (mainly pharmacological treatment)
Number of subjects: 272
Study 35288073 — intervention group
Group type: EXPERIMENTAL
Intervention: Ahmed glaucoma valve (model FP7)
Number of subjects: 621
Study 35288073 — intervention group
Group type: COMPARATOR
Intervention: Baerveldt glaucoma implant (model 101‐350)
Number of subjects: 621
Study 32448384 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental hip strengthening exercise (group C)
Number of subjects: 24
Study 32448384 — intervention group
Group type: COMPARATOR
Intervention: ITB stretching (group A)
Number of subjects: 24
Study 32448384 — intervention group
Group type: COMPARATOR
Intervention: Conventional exercise (group B)
Number of subjects: 24
Study 33390465 — intervention group
Group type: EXPERIMENTAL
Intervention: Sub-Cohort Study methodology including face-to-face assessment of neuropsychiatric development, body measurement, paediatrician's examination, blood/urine collection for clinical testing and chemical analysis, and home visits.
Number of subjects: 10302
Study 33390465 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up assessments at 1.5 and 3 years old for home visits, and 2, 4, 6, and 8 years old for developmental/medical examination.
Number of subjects: 10302
Study 32391579 — intervention group
Group type: EXPERIMENTAL
Intervention: DFMO maintenance therapy for HRNB after standard COG induction, consolidation and immunotherapy for 2 years
Number of subjects: 81
Study 32391579 — intervention group
Group type: COMPARATOR
Intervention: Historical control group (76 HRNB patients treated at Beat Childhood Cancer Research Consortium hospitals, disease-free after standard therapy, no DFMO)
Number of subjects: 81
Study 32722957 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotretinoin 0.5 mg/kg/day
Number of subjects: 0
Study 32722957 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 35550639 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote e-Consent implementation
Number of subjects: 63
Study 35550639 — intervention group
Group type: COMPARATOR
Intervention: Old methods of recruitment (in-person consent)
Number of subjects: 63
Study 32811628 — intervention group
Group type: EXPERIMENTAL
Intervention: EMI only
Number of subjects: 401
Study 32811628 — intervention group
Group type: EXPERIMENTAL
Intervention: EMA only
Number of subjects: 401
Study 32811628 — intervention group
Group type: EXPERIMENTAL
Intervention: Both EMI and EMA
Number of subjects: 401
Study 32811628 — intervention group
Group type: COMPARATOR
Intervention: Control condition (neither EMI nor EMA)
Number of subjects: 401
Study 36480039 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative telehealth call
Number of subjects: 0
Study 36480039 — intervention group
Group type: COMPARATOR
Intervention: No telehealth call (control)
Number of subjects: 0
Study 34114840 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized benchmarking algorithm using Weyl unitaries
Number of subjects: 0
Study 35093318 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids and nebulized epinephrine
Number of subjects: 210
Study 35093318 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 210
Study 34283997 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month, individually tailored, progressive, physiotherapist-supervised physical exercise twice a week (n=150)
Number of subjects: 300
Study 34283997 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n=149)
Number of subjects: 300
Study 32221070 — intervention group
Group type: EXPERIMENTAL
Intervention: HT CBP
Number of subjects: 95
Study 33358164 — intervention group
Group type: EXPERIMENTAL
Intervention: Zn amino acid complex (ZA; 40 mg/kg DM)
Number of subjects: 40
Study 33358164 — intervention group
Group type: COMPARATOR
Intervention: Heat stress (HS)
Number of subjects: 40
Study 33358164 — intervention group
Group type: COMPARATOR
Intervention: Heat stress (HS) and pair-fed (PF)
Number of subjects: 40
Study 33358164 — intervention group
Group type: COMPARATOR
Intervention: Heat stress and nutrient restriction
Number of subjects: 40
Study 33358164 — intervention group
Group type: COMPARATOR
Intervention: Pair-fed (PF)
Number of subjects: 40
Study 32398578 — intervention group
Group type: EXPERIMENTAL
Intervention: Semirecumbent position
Number of subjects: 36
Study 32398578 — intervention group
Group type: EXPERIMENTAL
Intervention: Right lateral position
Number of subjects: 36
Study 32398578 — intervention group
Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 36
Study 32398578 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (SR then RL)
Number of subjects: 36
Study 32398578 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (RL then SR)
Number of subjects: 36
Study 35139082 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual-benefits reminder
Number of subjects: 48125
Study 35139082 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual- and social-benefits reminder
Number of subjects: 48125
Study 35139082 — intervention group
Group type: COMPARATOR
Intervention: No reminder (control treatment)
Number of subjects: 48125
Study 35139082 — intervention group
Group type: EXPERIMENTAL
Intervention: Any type of reminder letter
Number of subjects: 48125
Study 35139082 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual-benefit reminder vs Individual- and social-benefit reminder
Number of subjects: 48125
Study 33259700 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized configuration targeted integration (RCTI) CLD approach for expression of complex molecules
Number of subjects: 0
Study 33259700 — intervention group
Group type: COMPARATOR
Intervention: Standard targeted integration (TI) CLD
Number of subjects: 0
Study 34851734 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (75 µg)
Number of subjects: 28
Study 34851734 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 28
Study 32197936 — intervention group
Group type: EXPERIMENTAL
Intervention: PSA-based screening (two rounds at 4-6 year intervals, biopsy recommended if PSA>=3.0 ng/mL)
Number of subjects: 80696
Study 32197936 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PSA testing information provided, physicians and patients' decision)
Number of subjects: 80696
Study 35201549 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized goal-directed hemodynamic management
Number of subjects: 180
Study 35201549 — intervention group
Group type: COMPARATOR
Intervention: Routine hemodynamic management
Number of subjects: 180
Study 35685659 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrowband Imaging (NBI) mode
Number of subjects: 64
Study 35685659 — intervention group
Group type: COMPARATOR
Intervention: Normal white light mode
Number of subjects: 64
Study 35685659 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS combined with NBI diagnosis
Number of subjects: 64
Study 32282882 — intervention group
Group type: EXPERIMENTAL
Intervention: IVMP 30 mg/kg followed by IVIG (Gamunex 10%) 1 g/kg
Number of subjects: 32
Study 32282882 — intervention group
Group type: COMPARATOR
Intervention: IVIG (placebo)
Number of subjects: 32
Study 32282882 — intervention group
Group type: EXPERIMENTAL
Intervention: IVMP + IVIG
Number of subjects: 32
Study 35355827 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral Sodium Fluoride (NaF) oral rinse (Colgate® PreviDent® Dental Rinse‐0.2% NaF) weekly for 6 months
Number of subjects: 90
Study 35355827 — intervention group
Group type: EXPERIMENTAL
Intervention: Acidulated Phosphate Fluoride (APF) oral rinse (Colgate® Ortho Defense@ PhosFlur® Rinse‐0.044% w/v of NaF) daily for 6 months
Number of subjects: 90
Study 34147154 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine mass drug administration (MDA) with a target total dose of 7 mg/kg dihydroartemisinin and 55 mg/kg piperaquine, delivered in three rounds over a period from March 4 to May 10, 2015.
Number of subjects: 2671
Study 34147154 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving routine malaria case management and long-lasting insecticidal bed-nets (LLINs) without MDA.
Number of subjects: 2671
Study 34147154 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events monitoring for individuals treated with MDA.
Number of subjects: 2671
Study 34028126 — intervention group
Group type: EXPERIMENTAL
Intervention: Neratinib plus Capecitabine (N + C) - Neratinib 240 mg per day, Capecitabine 750 mg/m2 twice daily
Number of subjects: 101
Study 34028126 — intervention group
Group type: COMPARATOR
Intervention: Lapatinib plus Capecitabine (L + C) - Lapatinib 1,250 mg per day, Capecitabine 1,000 mg/m2 twice daily
Number of subjects: 101
Study 34028126 — intervention group
Group type: EXPERIMENTAL
Intervention: Neratinib plus Capecitabine (N + C)
Number of subjects: 101
Study 34028126 — intervention group
Group type: COMPARATOR
Intervention: Lapatinib plus Capecitabine (L + C)
Number of subjects: 101
Study 34790253 — intervention group
Group type: EXPERIMENTAL
Intervention: Elgucare (Chinese herbal formula)
Number of subjects: 0
Study 34790253 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 0
Study 32709500 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital-based pulmonary rehabilitation (Group 1)
Number of subjects: 67
Study 32709500 — intervention group
Group type: COMPARATOR
Intervention: Home-based pulmonary rehabilitation (Group 2)
Number of subjects: 67
Study 36054295 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based primary care (HBPC)
Number of subjects: 229
Study 36054295 — intervention group
Group type: COMPARATOR
Intervention: Office-based primary care (Control)
Number of subjects: 229
Study 36858753 — intervention group
Group type: EXPERIMENTAL
Intervention: Written Exposure Therapy (WET)
Number of subjects: 123
Study 36858753 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Processing Therapy (CPT)
Number of subjects: 123
Study 32998825 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative balloon aortic valvuloplasty (BAV)
Number of subjects: 59
Study 32998825 — intervention group
Group type: COMPARATOR
Intervention: Control (no BAV)
Number of subjects: 59
Study 36436199 — intervention group
Group type: EXPERIMENTAL
Intervention: ICM implant with remote monitoring and symptom-triggered mobile app transmissions
Number of subjects: 477
Study 36436199 — intervention group
Group type: COMPARATOR
Intervention: Non-ICM management and follow-up
Number of subjects: 477
Study 33977624 — intervention group
Group type: EXPERIMENTAL
Intervention: Mutual aid relationships (family; family and intra-generational neighbors; family and multi-generational neighbors)
Number of subjects: 436
Study 33977624 — intervention group
Group type: EXPERIMENTAL
Intervention: No mutual aid
Number of subjects: 436
Study 32169019 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin vaginal gel (400 IU, n=48)
Number of subjects: 96
Study 32169019 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=48)
Number of subjects: 96
Study 35166715 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortical Bone Trajectory (CBT) fixation
Number of subjects: 80
Study 34548312 — intervention group
Group type: EXPERIMENTAL
Intervention: Procalcitonin guided antibiotics (n=195)
Number of subjects: 469
Study 34548312 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n=122)
Number of subjects: 469
Study 34548312 — intervention group
Group type: EXPERIMENTAL
Intervention: UltraPro (n=152)
Number of subjects: 469
Study 32331058 — intervention group
Group type: EXPERIMENTAL
Intervention: Esketamine nasal spray (56 mg or 84 mg) in combination with newly initiated oral antidepressant (ESK+AD)
Number of subjects: 0
Study 32331058 — intervention group
Group type: COMPARATOR
Intervention: Oral antidepressant + placebo nasal spray (AD+PBO)
Number of subjects: 0
Study 35413861 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) treatment thrice weekly for 4 weeks
Number of subjects: 108
Study 35413861 — intervention group
Group type: COMPARATOR
Intervention: Topical diclofenac sodium gel (DSG) at a dose of 2 g over the affected joints per hand, applied four times per day for 4 weeks
Number of subjects: 108
Study 33772892 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic alliance
Number of subjects: 169
Study 33772892 — intervention group
Group type: COMPARATOR
Intervention: Cognitive processing therapy (CPT)
Number of subjects: 169
Study 33833507 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized glycopyrrolate (GLY) 25 µg twice-daily (BID)
Number of subjects: 861
Study 33833507 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized glycopyrrolate (GLY) 25 µg BID
Number of subjects: 861
Study 33833507 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 861
Study 32410424 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal analgesia (MA) therapy including oral administration of celecoxib before operation, local anesthetic wound infiltration during operation, and ice compression and oral administration of celecoxib after operation.
Number of subjects: 60
Study 32410424 — intervention group
Group type: COMPARATOR
Intervention: Patient-controlled intravenous analgesia pump (Control group).
Number of subjects: 60
Study 32410424 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal analgesia (MA) therapy.
Number of subjects: 60
Study 37045683 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 + 1 schedule (doses at 3 and 12 months)
Number of subjects: 213
Study 37045683 — intervention group
Group type: COMPARATOR
Intervention: 2 + 1 schedule (two primary doses and a booster)
Number of subjects: 213
Study 33156372 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIIT)
Number of subjects: 82
Study 33156372 — intervention group
Group type: COMPARATOR
Intervention: Active video gaming (AVG)
Number of subjects: 82
Study 36366817 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-limb mask
Number of subjects: 10